These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12428082)

  • 41. A brief review on high on-aspirin residual platelet reactivity.
    Pettersen AA; Arnesen H; Seljeflot I
    Vascul Pharmacol; 2015; 67-69():6-9. PubMed ID: 25869498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aspirin resistance in atherosclerosis.
    Blair P; Freedman JE
    Curr Atheroscler Rep; 2008 Apr; 10(2):149-57. PubMed ID: 18417070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic determinants of response to aspirin: appraisal of 4 candidate genes.
    Lordkipanidzé M; Diodati JG; Palisaitis DA; Schampaert E; Turgeon J; Pharand C
    Thromb Res; 2011 Jul; 128(1):47-53. PubMed ID: 21429568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation.
    Undas A; Sanak M; Musial J; Szczeklik A
    Lancet; 1999 Mar; 353(9157):982-3. PubMed ID: 10459913
    [No Abstract]   [Full Text] [Related]  

  • 45. [Aspirin resistance].
    Yilmaz MB; Balbay Y; Korkmaz S
    Anadolu Kardiyol Derg; 2004 Mar; 4(1):59-62. PubMed ID: 15033621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital.
    Nidhinandana S; Changchit S
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S51-4. PubMed ID: 21280515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aspirin resistance: focus on clinical endpoints.
    Pusch G; Feher G; Kotai K; Tibold A; Gasztonyi B; Feher A; Papp E; Lupkovics G; Szapary L
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):475-84. PubMed ID: 19034037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
    Gasparyan AY; Watson T; Lip GY
    J Am Coll Cardiol; 2008 May; 51(19):1829-43. PubMed ID: 18466797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

  • 52. Invited commentary.
    Lee HS
    Ann Thorac Surg; 2007 Jan; 83(1):138-9. PubMed ID: 17184646
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of obesity on platelet reactivity and response to low-dose aspirin.
    Bordeaux BC; Qayyum R; Yanek LR; Vaidya D; Becker LC; Faraday N; Becker DM
    Prev Cardiol; 2010; 13(2):56-62. PubMed ID: 20377806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100.
    Madsen EH; Schmidt EB; Maurer-Spurej E; Kristensen SR
    Platelets; 2008 Aug; 19(5):335-41. PubMed ID: 18791939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
    Kobzar G; Mardla V; Samel N
    Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The anti-platelet aggregation drugs: new approaches based on snake venom polypeptides].
    Marrakchi N; Guermazi S; El Ayeb M
    Arch Inst Pasteur Tunis; 1997; 74(1-2):9-15. PubMed ID: 15945171
    [No Abstract]   [Full Text] [Related]  

  • 57. Aspirin, NSAIDs, and cardiovascular risk: is there a link?
    Kapoor JR
    Am J Med; 2008 Nov; 121(11):e9. PubMed ID: 18954833
    [No Abstract]   [Full Text] [Related]  

  • 58. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin.
    Al-Azzam SI; Alzoubi KH; Khabour OF; Tawalbeh D; Al-Azzeh O
    Gene; 2013 Sep; 526(2):118-21. PubMed ID: 23688555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelets, aspirin and cardiovascular disease.
    Elwood PC
    J R Coll Physicians Lond; 1976 Jul; 10(4):347-50. PubMed ID: 957271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.